+
Covestro Begins Local Medical-Grade TPU Production in Taiwan
ECONOMY & POLICY

Covestro Begins Local Medical-Grade TPU Production in Taiwan

Covestro has launched localised production of medical-grade Thermoplastic Polyurethane (TPU) at its Changhua site in Taiwan, marking its first such facility in the Asia Pacific region. The site, now qualified for medical-grade TPU manufacturing, will produce Desmopan® Rx grades, enabling faster and more secure regional supply for high-performance medical applications.

This is Covestro’s second global site after New Martinsville, North America, to manufacture medical-grade TPU. The move reflects rising demand driven by improved healthcare standards and an ageing global population.

Meeting Global Standards, Serving Regional Needs

Manufactured in line with Good Manufacturing Practice (GMP) guidelines, Desmopan® Rx grades meet international medical standards including ISO 10993 and China’s YY/T 1557, ensuring biocompatibility and minimised contamination risks. Free from added plasticisers, the TPU grades offer low extractables and are compatible with multiple sterilisation methods.

Dr Frank Yang, Head of Asia-Pacific Innovation TPU at Covestro, stated: “Our Desmopan® Rx grades meet established medical industry standards. This production shift ensures product safety, compliance, and timely delivery for regulated Asian markets.”

Designed for Advanced Medical Use

Desmopan® Rx TPUs are tailored for a wide range of medical devices, including tubing, catheters, connectors, housings, endoscopes, and wearable devices. Their use spans surgical procedures, drug delivery, dialysis, wound care, and more.

The material’s benefits include:

  • Biocompatibility for patient-contact use
  • High clarity for medical observation
  • Kink resistance for uninterrupted fluid flow
  • Excellent chemical and abrasion resistance
  • Superior flexibility and dimensional stability

Additionally, Desmopan® Rx is suitable for melt-blown medical nonwovens used in drapes, gowns, sterile packaging, and PPE, offering strong performance while complying with medical waste regulations.

Strengthening Regional Infrastructure

The Changhua facility complements Covestro’s Zhuhai production base and its new application development centre in Guangzhou, enhancing local innovation and delivery capabilities. Kevin Ho, Head of Sales and Market Development TPU Asia Pacific, noted, “With Changhua online, we can now shorten lead times and improve supply reliability for the region.”

Covestro is showcasing the Desmopan® Rx range at Booth N5E24 during CPHI & PMEC China, running through 26 June at the Shanghai New International Expo Center.

Covestro has launched localised production of medical-grade Thermoplastic Polyurethane (TPU) at its Changhua site in Taiwan, marking its first such facility in the Asia Pacific region. The site, now qualified for medical-grade TPU manufacturing, will produce Desmopan® Rx grades, enabling faster and more secure regional supply for high-performance medical applications.This is Covestro’s second global site after New Martinsville, North America, to manufacture medical-grade TPU. The move reflects rising demand driven by improved healthcare standards and an ageing global population.Meeting Global Standards, Serving Regional NeedsManufactured in line with Good Manufacturing Practice (GMP) guidelines, Desmopan® Rx grades meet international medical standards including ISO 10993 and China’s YY/T 1557, ensuring biocompatibility and minimised contamination risks. Free from added plasticisers, the TPU grades offer low extractables and are compatible with multiple sterilisation methods.Dr Frank Yang, Head of Asia-Pacific Innovation TPU at Covestro, stated: “Our Desmopan® Rx grades meet established medical industry standards. This production shift ensures product safety, compliance, and timely delivery for regulated Asian markets.”Designed for Advanced Medical UseDesmopan® Rx TPUs are tailored for a wide range of medical devices, including tubing, catheters, connectors, housings, endoscopes, and wearable devices. Their use spans surgical procedures, drug delivery, dialysis, wound care, and more.The material’s benefits include:Biocompatibility for patient-contact useHigh clarity for medical observationKink resistance for uninterrupted fluid flowExcellent chemical and abrasion resistanceSuperior flexibility and dimensional stabilityAdditionally, Desmopan® Rx is suitable for melt-blown medical nonwovens used in drapes, gowns, sterile packaging, and PPE, offering strong performance while complying with medical waste regulations.Strengthening Regional InfrastructureThe Changhua facility complements Covestro’s Zhuhai production base and its new application development centre in Guangzhou, enhancing local innovation and delivery capabilities. Kevin Ho, Head of Sales and Market Development TPU Asia Pacific, noted, “With Changhua online, we can now shorten lead times and improve supply reliability for the region.”Covestro is showcasing the Desmopan® Rx range at Booth N5E24 during CPHI & PMEC China, running through 26 June at the Shanghai New International Expo Center.

Next Story
Infrastructure Transport

Hubballi Airport Upgrade to Host Bigger Aircraft Soon

Hubballi airport will soon be capable of accommodating larger aircraft such as the Airbus A320, as apron expansion and reconfiguration works progress. Once completed, the upgraded apron will allow for 10 larger aircraft and four smaller aircraft to be parked simultaneously.This project forms part of a broader airport upgradation initiative, which includes construction of a new eco-friendly terminal building, additional apron bays, four aerobridges, and supporting infrastructure. The total development cost is Rs 2.7 billion.The Airports Authority of India (AAI) has floated a tender worth Rs 350..

Next Story
Infrastructure Transport

BMRCL Gets Only 9 Acres for Hebbal Metro Hub

A high-level committee chaired by Chief Secretary Shalini Rajneesh has approved the allocation of nine acres of land near Hebbal to the Bangalore Metro Rail Corporation Limited (BMRCL), significantly reducing the original request of 45 acres. The decision was made despite appeals from notable figures such as Biocon founder Kiran Mazumdar-Shaw, former Infosys director Mohandas Pai, and Minister of State Shobha Karandlaje, who represents Bengaluru North in the Lok Sabha.Initially, BMRCL had planned a state-of-the-art multi-modal transport hub and had sought 45.5 acres for the purpose. However, i..

Next Story
Infrastructure Energy

CCI Approves Wind Power Deal Involving TPG and SGRE

The Competition Commission of India (CCI) has approved the proposed acquisition of the Target Business from Siemens Gamesa Renewable Energy (SGRE) and its Sri Lankan arm SGREL by a consortium including Peony Properties Private Limited (PPPL), TPG REGen SG Pte. Ltd. (TPG REGen), Mavco Investments Private Limited (Mavco), Tikri Investments (Tikri), and SGRE.The Target Business includes the manufacture and assembly of onshore wind turbine generators, as well as the provision of operation, maintenance, and technical services for wind turbines and onshore wind power projects. These operations are c..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?